Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSNKY
Rang in Aktien #660
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports,... Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.
Aktienkurs
$17.64
Marktkapitalisierung
$32.65B
Veränderung (1 Tag)
-3.24%
Veränderung (1 Jahr)
-23.70%
Land
JP
Handel Daiichi Sankyo Company, Limited (DSNKY)

Kategorie

Operative Marge für Daiichi Sankyo Company, Limited (DSNKY)
Operative Marge zum March 2026 TTM: 13.90%
Laut den neuesten Finanzberichten und dem Aktienkurs von Daiichi Sankyo Company, Limited beträgt die aktuelle operative Marge (TTM) 13.90%. Am Ende des Jahres 2024 lag die operative Marge bei 11.50%.
Historie der operativen Marge von Daiichi Sankyo Company, Limited von 2000 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) 13.90% -13.56%
2025 16.08% 39.83%
2024 11.50% 43.93%
2023 7.99% -42.85%
2022 13.98% 5.43%
2021 13.26% -53.10%
2020 28.27% 56.97%
2019 18.01% 13.34%
2018 15.89% -14.66%
2017 18.62% -29.58%
2016 26.44% 63.31%
2015 16.19% 21.64%
2014 13.31% 32.17%
2013 10.07% -3.73%
2012 10.46% -17.18%
2011 12.63% 25.92%
2010 10.03% -4.93%
2009 10.55% -40.80%
2008 17.82% 21.47%
2007 14.67% -12.21%
2006 16.71% 15.64%
2005 14.45% -9.80%
2004 16.02% 14.35%
2003 14.01% -4.63%
2002 14.69% -8.81%
2001 16.11% -33.43%
2000 24.20% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
45.56% -96.72%
US
23.28% -98.33%
GB
27.17% -98.05%
US
26.72% -98.08%
US
31.24% -97.75%
CH
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.